Latanoprost Sandoz (Latanoprost)

Latanoprost is a prostaglandin F2α analogue that binds to FP receptors in the ciliary body. This binding remodels the extracellular matrix, increasing uveoscleral outflow of aqueous humor and thereby reducing intraocular pressure.

The dosing regimen is determined by the prescribing eye‑care professional. Typically, one drop is instilled in each affected eye once daily in the evening, but patients must follow the specific instructions provided by their clinician.

Safety data are limited; the product is classified as pregnancy category unknown. It is generally recommended to avoid use during pregnancy or lactation unless the potential benefit justifies the risk as assessed by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with beta‑blocker eye drops, latanoprost often provides greater intraocular pressure reduction with once‑daily dosing and a distinct side‑effect profile. It is considered a first‑line therapy alongside other prostaglandin analogues for many patients.

Store the ophthalmic solution at room temperature, below 25 °C, in the original container. Protect it from light and moisture, keep the bottle tightly closed, and do not freeze.

Latanoprost is supplied as an eye drop solution. The patient places one drop into each prescribed eye, usually in the evening, taking care not to let the tip touch the eye or surrounding surfaces to maintain sterility.

Rare but serious adverse events include severe eye inflammation, allergic reactions, corneal edema, and a sudden increase in intraocular pressure. Patients should seek immediate medical attention if they experience pain, marked redness, vision loss, or any rapid change in eye condition.

Individuals with active ocular infections, inflammation, or a known hypersensitivity to latanoprost or any excipients in the formulation should avoid using this product. Consultation with an eye‑care professional is required before initiating therapy.